CARCINOMA, NON-SMALL-CELL LUNG

This study tested a new immunotherapy drug, cemiplimab, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). About 700 patients participated. The goal was to see if cemiplimab helps people live longer and keeps the …

This study looked at how well the drug Tagrisso works for people with a certain type of advanced lung cancer in everyday medical practice, not just in strict research settings. Over 900 patients in Korea took part, and researchers tracked side effects and how long the drug kept t…

This study tested two experimental drugs, BI 754111 and BI 754091, that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found a safe dose; the sec…

This study tracked 296 people with advanced or recurrent non-small cell lung cancer who received a combination of IMJUDO, IMFINZI, and platinum-based chemotherapy. The goal was to see how safe the treatment is when used in everyday medical practice. Researchers recorded any side …

This study tested a combination of two targeted drugs, dabrafenib and trametinib, in 40 Chinese adults with a specific type of advanced lung cancer (BRAF V600E mutation-positive, stage IV non-small cell lung cancer). The goal was to see how well the treatment shrank tumors and to…

This study tested whether giving palliative radiotherapy to 2-5 metastatic sites before starting first-line immunotherapy and chemotherapy can improve outcomes for people with advanced non-small cell lung cancer. 50 participants with PD-L1 below 50% received this combined approac…

This early-phase study tested a new drug called boserolimab, given alone or with pembrolizumab, in 182 adults with advanced solid tumors (including lung and breast cancers). The main goals were to check safety and how the drug moves through the body. Participants received treatme…

This study tested whether adding an investigational drug (MK-4830 or MK-0482) to the standard immunotherapy pembrolizumab can help shrink tumors or slow cancer growth in people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). About 100 adults …

This study tested whether adding a new drug (LY2875358) to the standard treatment erlotinib works better than erlotinib alone for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). All 168 participants took erlotinib for 8 weeks first…

This study tested a combination of two drugs (atezolizumab and cabozantinib) against a standard chemotherapy (docetaxel) in 366 people with advanced non-small cell lung cancer that had worsened after prior treatments. The goal was to see if the combination helped people live long…

This study tested whether adding one of three experimental drugs to pembrolizumab (an immunotherapy) can help shrink tumors or slow disease in 128 adults with advanced non-small cell lung cancer that had already been treated with a similar immunotherapy. Participants received the…

This study tested a drug called lorlatinib in 109 people in China with a specific type of advanced lung cancer (ALK-positive non-small cell lung cancer) that had gotten worse after treatment with other ALK-targeting medicines. The goal was to see if lorlatinib could shrink tumors…

This study tested a drug called cabozantinib, either alone or with another drug (erlotinib), in people with advanced non-small cell lung cancer whose cancer had stopped responding to erlotinib. The goal was to find safe doses and see if the combination could shrink tumors. 92 adu…

This study tested a combination of two drugs—bevacizumab and a higher dose of icotinib—in 35 people with advanced non-squamous lung cancer that has a specific EGFR mutation (L858R). The goal was to see if the combo could delay cancer growth better than standard treatment. Partici…

This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the …

This study tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combo could shrink tumors a…

This study tested a combination of two drugs, SHR-1210 and apatinib, in 210 people with advanced non-small cell lung cancer that had stopped responding to earlier treatments. The goal was to see if the combination was safe and could shrink tumors. Participants received the drugs …

This early-phase study tested whether giving patients their own specially grown natural killer (NK) cells, combined with the drug bortezomib, is safe for people with advanced solid tumors or leukemia that no longer respond to standard treatments. 35 adults received increasing dos…

This early-stage study tested a new drug called SGN-B6A in 6 Chinese patients with advanced solid tumors (lung, head and neck, esophageal, or stomach cancers). The main goal was to check for side effects and see how the body processes the drug. It was not designed to measure if t…

This study looked at whether a new biomarker called 'mass response' can help predict how well cancer treatments will work. Researchers collected tumor cells from 72 adults with various cancers using fluid samples or biopsies. The goal was to see if this biomarker could guide ther…